Evidence map›Paper›PMID 40574035›Full record

ArticlePharmaceutics2025

Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations.

Sijongesonke Peter, Eric Morifi, Mutshinyalo Nwamadi, Samson Olaitan Oselusi, Asongwe Lioniel Tantoh, Thierry Youmbi Fonkui, Derek Tantoh Ndinteh, Blessing Atim Aderibigbe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sijongesonke PeterDepartment of Chemistry, University of Fort Hare, Alice Campus, Dikeni 5700, South Africa.ORCID 0000-0002-6935-905X
Eric MorifiSchool of Chemistry, Mass Spectrometry Division, University of Witwatersrand, Johannesburg 2017, South Africa.
Mutshinyalo NwamadiDepartment of Chemistry, University of Johannesburg, Auckland Park Campus, Johannesburg 2017, South Africa.
Samson Olaitan OselusiDepartment of Biotechnology, University of the Western Cape, Bellville, Cape Town 7535, South Africa.ORCID 0000-0003-4736-0823
Asongwe Lioniel TantohPharmaceutical, Future Production Chemical Cluster, Council for Scientific and Industrial Research (CSIR), Meiring Naude Road, Brummeria, P.O. Box 395, Pretoria 0001, South Africa.
Thierry Youmbi FonkuiDepartment of Biotechnology, University of Johannesburg, Doornfontein Campus, Johannesburg 2092, South Africa.
Derek Tantoh NdintehDepartment of Chemical Sciences, University of Johannesburg, Doornfontein Campus, Johannesburg 2092, South Africa.
Blessing Atim AderibigbeDepartment of Chemistry, University of Fort Hare, Alice Campus, Dikeni 5700, South Africa.ORCID 0000-0003-1157-7481

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibacterialanticancerdrug resistanceferrocenehybridspharmacokinetics

Identifiers

PMID40574035
PMCPMC12195905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.